Syringes (Global Market)

Syringes (Russian market)

Main article: Syringes (Russian market)

Syringe pens and autoinjectors

Main article: Syringe pens and autoinjectors

Chronicle

2024: Global Market Size for Finished Syringes Reaches $8.47 Billion for the Year

At the end of 2024, the global market for pre-filled (ready-made) syringes amounted to $8.47 billion. About 40% of global costs fell on the European region. This is stated in a study by Fortune Business Insights, the results of which were published on July 14, 2025.

Finished syringes are a disposable injection system filled with a certain amount of a particular substance. Such devices improve the convenience and accuracy of drug administration while providing greater safety for both patients and healthcare professionals. In particular, the probability of accidental needles injections is reduced, and errors with dosage are minimized.

𝓲

Фото: Freepik

One of the key applications of pre-filled syringes is vaccination of the population. These drugs are critical to preventing the spread of infectious diseases, and ready-made syringes with the right amount of substance eliminate the need for manual measurement and reduce the risk of infection. In addition, similar syringes are often used to administer drugs for chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis. According to the World Health Organization (WHO), from 1990 to 2022, the number of people with diabetes increased from 200 million to 830 million people, that is, more than four times. The prevalence of this disease among the adult population rose from 7% to 14%. Many people with diabetes require regular insulin injections. The precise dosage and ease of use of the finished syringes ensures that patients receive the required amount of the drug each time, which reduces the likelihood of complications.

According to the type of material used, finished syringes are divided into glass and plastic (polymer) products. In 2024, it is estimated that type one products dominated. Many pharmaceutical manufacturers still favor glass due to its properties. However, there has been a gradual transition to alternative materials, such as a cycloolefin polymer, which combines high transparency and strength. New generation polymers have other advantages, including high chemical stability and design flexibility.

By application, the market is segmented into rheumatoid arthritis, cancer, diabetes, etc. In 2024, the first of these sectors provided the largest revenue, which is explained by the growing prevalence of the disease. According to WHO estimates, in 2019, 18 million people worldwide suffered from rheumatoid arthritis. About 70% of patients are women, and 55% are people over the age of 55. At the same time, the highest growth rates of sales of finished syringes are recorded in the direction of cancer.

Geographically, in 2024, Europe was the leader, which accounted for 40.6% of sales, or $3.44 billion. North America is in second place in terms of spending. Globally, the leading players are:

• BD (Becton, Dickinson and Company);
• Schott Pharma;
• Gerresheimer AG;
• West Pharmaceutical Services;
• Nipro Group Companies;
• AptarGroup;
• Terumo Corporation;
• Ypsomed AG.

In 2025, the pre-filled syringe market size is expected to reach $9.15 billion. Fortune Business Insights analysts believe that in the future, the CAGR will be 10.8%. Thus, by 2032, costs may increase to $18.73 billion.^[1]

Notes